top of page

Jefferies London 2026: IDEAYA Biosciences Founder & CEO Yujiro Hata shares an update on darovasertib, which is in front of FDA for Uveal Melanoma, and talks DLL3 and PRMT5

1 hour ago
1 min read

He describes the darovasertib filing, which IDEAYA hopes will be for all metastatic uveal melanoma patients. Plus, what makes DLL3 a compelling target, and how interest in PRMT5 has especially taken off given how prevalent MTAP deletions are in pancreatic cancer.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page